Studybox Research CLIA Waiver Studies

HIV Rapid Test

Accuracy in the hands of untrained intended-use operators at waived sites.

Studybox

CLIA Waiver Studies

HIV diagnostic tests have historically been regulated through premarket approval by FDA's biologics center rather than through 510(k), which places them outside the dual-submission pathway described elsewhere on this site. CLIA waiver for an approved rapid HIV test is obtained through a waiver application supported by a study of untrained operators in waived settings, and that is the study described here. Sponsors should confirm the current classification and premarket route for their device before planning.

The waived-setting study enrolls at sites representative of where rapid HIV testing happens: community testing programs, sexual health clinics, pharmacies, emergency departments and primary care. Sensitivity data come mostly from known-positive subjects, often people already in care, while specificity comes from large numbers of people at low risk. False positives have direct consequences for the person tested, and specificity in untrained hands is scrutinized closely.

Analyte: HIV-1 and HIV-2 antibodies, with or without HIV-1 p24 antigen
Therapeutic area: STD/STI Detection
Specimens: Capillary Fingerstick Blood, Venous Whole Blood, Serum and Plasma
Intended-use settings: urgent care, physician office, pharmacy, home use, emergency department
Operators: Non-laboratory staff in waived settings including community testing programs, pharmacies and clinics; lay users for self-test versions.
Comparator: Typically the laboratory HIV diagnostic algorithm: an FDA-approved HIV-1/2 antigen/antibody immunoassay followed by an HIV-1/HIV-2 antibody differentiation assay, with nucleic acid testing to resolve discordant or acute-infection cases.

CLIA Waiver Studies specifics

What Changes for This Assay on This Pathway.

Because premarket approval has already established clinical performance, the waiver study focuses on whether untrained operators at waived sites reproduce that performance on fingerstick whole blood, with attention to collecting the specified volume from the fingertip and to read-time compliance.
Specificity among low-prevalence subjects at waived sites is the endpoint most sensitive to operator error (reading a faint line as positive) and typically carries the most weight in review.
Flex studies typically stress read window (early and late reads), blood volume applied, buffer drop count and kit storage temperature, and should include the humid, bright or dim conditions typical of outreach settings.
Known-positive subjects are typically people living with HIV on antiretroviral therapy, whose antibody levels remain detectable; the protocol should state whether treated subjects count toward sensitivity and whether seroconversion panels supplement them.

Endpoints the study must support

Sensitivity in subjects with confirmed HIV infection, reported separately for HIV-1 and HIV-2 where claimed, with 95% confidence intervals
Specificity in a low-prevalence population representative of intended use settings
For antigen/antibody devices, detection in seroconversion panels and in subjects with acute infection relative to the laboratory algorithm
Invalid rate and, for self-testing claims, lay user agreement and result interpretation

Enrollment realities

Known-positive enrollment is the limiting arm and usually depends on partnerships with HIV clinics; specificity enrollment at waived sites is large but accrues quickly. Acute-infection cases for antigen/antibody claims are rare and typically supplemented with characterized seroconversion panels.

How Studybox runs it

Pre-Qualified Sites, Embedded Coordinators.

Waiver evidence depends on genuine intended-use operators in genuine waived settings. Our network of 100+ pre-qualified urgent care, physician office, and point-of-care sites already runs IVD protocols, so operator recruitment and site activation don't start from zero. How we run clia waiver studies →

Relevant FDA guidance

FAQ

HIV Rapid Test Study Questions.

01 Who operates the hiv rapid test in a clia waiver studies study?

Non-laboratory staff in waived settings including community testing programs, pharmacies and clinics; lay users for self-test versions.

02 What is the comparator for a hiv rapid test study?

Typically the laboratory HIV diagnostic algorithm: an FDA-approved HIV-1/2 antigen/antibody immunoassay followed by an HIV-1/HIV-2 antibody differentiation assay, with nucleic acid testing to resolve discordant or acute-infection cases.

03 What drives enrollment for a hiv rapid test study?

Let's talk IVD research

Planning a hiv rapid test study?

Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the clia waiver studies pathway.